Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma